|
05/21/2013 09:15:50
Index/Home
Cryme Trainer (moved)
Non-HLA-linked Diseases
Hurricane Sandy and Mold-Related
illnesses (like LYMErix and Lyme Disease, and CFIDS/FM).
=======
References for
psychotropics-induced brain damage
Older data on the incurability of
Relapsing Fever
1986, McSweegan trashes Navy
for $$$ for ALDF.com
1988, Dattwyler & about
immune-suppressing, seronegative Lyme
1990, CDC: "Diagnose Lyme
as if it was Relapsing Fever."
Allen Steere
"NeuroLyme won't test positive," 1990.
1992, CDC officer Allen
Steere falsifies testing in Europe
1992, CDC
patents with SmithKline show 2 kinds of Lyme
Compare the 2 kinds of
Lyme in the RICO complaint
1994, CDC's Dearborn Booklet
.pdf
CDC's invitation to
participate in Dearborn .pdf
Igenex, Harris,
Dearborn .pdf
Evidence
Lyme criminals knew LYMErix produced the same "multisystem disease" as "Chronic
Lyme"
LYMErix Damage Coverup
(short)
120302 NIH Treatments
1998, CIA Oilmen & Israelis plan to overthrow
Saddam for the oil.
Bush/Gore Oil/War-(Oct,2000)
Bush's own explainer (Oct
2000) re:
Iraq Oil
| |
On this page is a snippet from a report by Yale's Erol Fikrig in which he
reveals that OspA cannot be used as a vaccine - it is a relapsing fever
organism, the nature of the relapse is antigenic variation, so antibodies
made are soon rendered useless, as the bugs produces a whole new slew of
outer surface antigens....
Additionally, the full text of the CDC officer Alan Barbour reporting that
OspA can not be used as a vaccine because it, OspA, too, undergoes antigenic
variation,
HERE. [Alan Barbour holds the
patent for the Pasteur Connaught (now Aventis) ImmuLyme OspA vaccine that
also failed and was falsely
reported as safe and effective by Lenny Sigal, et al in 1998.]
One would have to be a
STUPID
male to ever think there could be a vaccine for Relapsing Fever. "Selection pressure" is the term
that means "antibodies against specific antigens of Borreliae are rendered
useless due to antigenic variation, which means there can never be a vaccine for
relapsing fever borreliosis or Lyme borreliosis." (See also the
McSweegan letter to Barry Goldwater and
how Sweeg had no idea what "relapsing fever" even meant, or that his "cloned
ehrlichial ligands" also undergo selection pressure and cannot ever be
vaccines. What a complete idiot...)
070830;0520
It was a very stupid
idea- a vaccine for Relapsing Fever.
The nature of the relapse is the exact reason there can be no vaccine.


Yale's Erol Fikrig publishes above that antibodies
(created by either human infection or vaccine) create "selection pressure."
That's the newer term for "antibodies causing the surface antigen changes that
cause the relapse which is the reason there can never be a vaccine for Relapsing
Fever."
Here is the link to that full text report:
http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=173206&blobtype=pdf
You can see below that CDC "officer" Alan Barbour publishes the exact same
thing in 1992, in the next abstract. He uses monoclonal antibodies to "select for
variants" all the time. He also reports that OspA and B do true
antigenic variation.
Antibody-resistant mutants of Borrelia burgdorferi: in
vitro selection and characterization.
Department of Microbiology, University
of Texas Health Science Center, San Antonio 78284.
We used polyclonal antisera and monoclonal
antibodies (mAbs) to inhibit the growth of clonal populations of two strains
of Borrelia burgdorferi, the Lyme disease agent, and thereby select for
antibody-resistant mutants. mAbs were directed at the outer membrane proteins,
OspA or OspB. Mutants resistant to the growth-inhibiting properties of the
antibodies were present in the populations at frequencies ranging from 10(-5)
to 10(-2). The several escape variants that were examined were of four
classes. Class I mutants were resistant to all mAbs; they lacked OspA and OspB
and the linear plasmid that encodes them. Two other proteins were expressed in
larger amounts in class I mutants; mAbs to these proteins inhibited the mutant
but not the wild-type cells. Class II mutants were resistant to some but not
all mAbs; they had truncated OspA and/or OspB proteins. Class III mutants were
resistant only to the selecting mAb; they had full-length Osp proteins that
were not bound by the selecting antibody in Western blots. In two class III
mutants resistant to different anti-OspA mAbs, missense mutations were
demonstrated in the ospA genes. Class IV mutants were likewise resistant only
to selecting antibody, but in this case the selecting antibody still bound in
Western blots. PMID: 1339462 [PubMed - indexed for MEDLINE]
This means these guys all knew all along
there could never be a vaccine for borrreliosis. Alan Barbour owns
the patent for ImmuLyme or the other OspA vaccine.
Go here for lots
of patent data and information about how OspA causes
Immune-Suppression-related illnesses. It's at the bottom of that web
page.
|